Effect of Ivermectin Metabolites on Mosquito Survival
Status:
Recruiting
Trial end date:
2022-11-06
Target enrollment:
Participant gender:
Summary
This clinical trial will be designed to capture the full duration of mosquito-lethal effect
of single dose Ivermectin to aid efforts to characterize metabolites with mosquito-lethal
effect. Ivermectin and its metabolites likely have antiparasitic properties against asexual
and sexual stage Plasmodium parasites that will be investigated with plasma samples from this
study.
This is an open-label pharmacokinetic study. Ten healthy participants will be admitted in the
inpatient ward to receive a single oral dose of IVM (400 µg/kg).
Another 10 healthy participants will be donate blood up to 42 ml each times for up to 3
times. There is no drug administration for these participants.
The total duration for each volunteer's participation in the study is approximately 2 months.